| Literature DB >> 35688710 |
Saeed Pourmand1, Sara Zareei2, Mohsen Shahlaei3, Sajad Moradi4.
Abstract
The outbreak of COVID-19 has resulted in millions of deaths. Despite all attempts that have been made to combat the pandemic, the re-emergence of new variants complicated SARS-CoV-2 eradication. The ongoing global spread of COVID-19 demands the incessant development of novel agents in vaccination, diagnosis, and therapeutics. Targeting receptor-binding domain (RBD) of spike protein by which the virus identifies host receptor, angiotensin-converting enzyme (ACE2), is a promising strategy for curbing viral infection. This study aims to discover novel peptide inhibitors against SARS-CoV-2 entry using computational approaches. The RBD binding domain of ACE2 was extracted and docked against the RBD. MMPBSA calculations revealed the binding energies of each residue in the template. The residues with unfavorable binding energies were considered as mutation spots by OSPREY. Binding energies of the residues in RBD-ACE2 interface was determined by molecular docking. Peptide inhibitors were designed by the mutation of RBD residues in the virus-receptors complex which had unfavorable energies. Peptide tendency for RBD binding, safety, and allergenicity were the criteria based on which the final hits were screened among the initial library. Molecular dynamics simulations also provided information on the mechanisms of inhibitory action in peptides. The results were finally validated by molecular docking simulations to make sure the peptides are capable of hindering virus-host interaction. Our results introduce three peptides P7 (RAWTFLDKFNHEAEDLRYQSSLASWN), P13 (RASTFLDKFNHEAEDLRYQSSLASWN), and P19 (RADTFLDKFNHEAEDLRYQSSLASWN) as potential effective inhibitors of SARS-CoV-2 entry which could be considered in drug development for COVID-19 treatment.Entities:
Keywords: Antiviral peptide; COVID-19; Peptide design; SARS-CoV-2; Viral entry inhibitors
Mesh:
Substances:
Year: 2022 PMID: 35688710 PMCID: PMC9110306 DOI: 10.1016/j.compbiomed.2022.105625
Source DB: PubMed Journal: Comput Biol Med ISSN: 0010-4825 Impact factor: 6.698
Fig. 1The research overall design and flow process.
Fig. 2The illustration of (A) ACE2-RBD complex and (B) the interactions made by ACE2 and SARS-Cov-2 RBD. The viral residues with hydrogen bonds and hydrophobic forces are indicated by pink and blue fonts and the green and black fonts indicate ACE2 residues with hydrophobic and hydrogen bonds, respectively. The atoms with H-bonds are connected with green dashed lines.
The mmpbsa energy analysis of the template residues revealed by a 100-ns MD simulation.
| Template Residue | ΔG binding (kJ/mol) |
|---|---|
| 24GLN | 64.533 |
| 25ALA | −5.905 |
| 26LYS | 77.717 |
| 27THR | −20.011 |
| 28PHE | −21.064 |
| 29LEU | −5.489 |
| 30ASP | −74.37 |
| 31LYS | 52.018 |
| 32PHE | −3.903 |
| 33ASN | −8.814 |
| 34HIS | −0.822 |
| 35GLU | −80.445 |
| 36ALA | −0.604 |
| 37GLU | −116.525 |
| 38ASP | −107.831 |
| 39LEU | −5.742 |
| 40PHE | 0.095 |
| 41TYR | −13.531 |
| 42GLN | −3.413 |
| 43SER | −5.584 |
| 44SER | −4.1 |
| 45LEU | −16.746 |
| 46ALA | −7.268 |
| 47SER | −6.086 |
| 48TRP | −14.855 |
| 49ASN | −111.155 |
The inhibitory peptides with the highest OSPREY scores and the assessment of their allergenicity.
| ID | Peptide Inhibitor | OSPERY Score | Allergenicity |
|---|---|---|---|
| 1 | RARTFLDKFNHEAEDLRYQSSLASWN | −90.6 | PROBABLE ALLERGEN |
| 109 | DARTFLDKFNHEAEDLRYQSSLASWN | −79.6 | PROBABLE ALLERGEN |
| 19 | |||
| 37 | WARTFLDKFNHEAEDLRYQSSLASWN | −74.7 | PROBABLE ALLERGEN |
| 4 | RARTFLDKFNHEAEDLDYQSSLASWN | −73.4 | PROBABLE ALLERGEN |
| 181 | TARTFLDKFNHEAEDLRYQSSLASWN | −72.6 | Non |
| 7 | |||
| 73 | SARTFLDKFNHEAEDLRYQSSLASWN | −72.4 | PROBABLE ALLERGEN |
| 31 | RATTFLDKFNHEAEDLRYQSSLASWN | −71.9 | PROBABLE ALLERGEN |
| 13 | |||
| 2 | RARTFLDKFNHEAEDLWYQSSLASWN | −71.7 | PROBABLE ALLERGEN |
The comparison of sequence, binding affinities (docking scores), and interactions of the template and top hits of computationally improved peptides binding. The residues involved in H-binding are indicated in bold.
| ID | Sequence | Clus Pro Docking Score | Residues | |
|---|---|---|---|---|
| Spike RBD | Peptide | |||
| Template | QAKTFLDKFNHEAEDLFYQSSLASWN | −700.6 | ||
| P7 | RAWTFLDKFNHEAEDLRYQSSLASWN | −761.6 | Ala25, | |
| P13 | RASTFLDKFNHEAEDLRYQSSLASWN | −726.6 | Thr27, Phe28, | |
| P19 | RADTFLDKFNHEAEDLRYQSSLASWN | −730.1 | ||
| P181 | TARTFLDKFNHEAEDLRYQSSLASWN | −673.1 | Thr27, | |
Fig. 3The representations of the best docking pose of top three peptides (A) P7, B) P13, and C) P19) bound to the RBD (gray) domain of the SARS-CoV-2 with the best docking scores.
Fig. 4Trajectory analysis of the final peptide hits compared to the template in terms of RMSD(A), Rg(B), SASA(C), and RMSF (D) in complex with RBD domain of SARS-CoV-2 spike.
The frequency of secondary structures in RBD in complex with selected peptides compared with the template.
| ID | Structure | Coil | B-Sheet | B-Bridge | Bend | Turn | A-Helix | 3-Helix |
|---|---|---|---|---|---|---|---|---|
| Template | 0.49 | 0.32 | 0.28 | 0.02 | 0.16 | 0.11 | 0.08 | 0.03 |
| P7 | 0.49 | 0.32 | 0.26 | 0.03 | 0.17 | 0.1 | 0.1 | 0.02 |
| P13 | 0.49 | 0.33 | 0.26 | 0.03 | 0.16 | 0.08 | 0.12 | 0.02 |
| P19 | 0.48 | 0.31 | 0.26 | 0.03 | 0.17 | 0.11 | 0.08 | 0.03 |
Fig. 5Trajectory analysis of the final peptide hits compared to the template in terms of RMSD(A), Rg(B), SASA(C), and RMSF (D) in complex with RBD domain of SARS-CoV-2 spike.
Fig. 6Estimation of hydrogen bonds of candidate peptides P7 (A), P13 (B), and P19(C) with RBD domain of SARS-CoV-2 spike over the span of 100 ns?
Energy profiles of RBD domain of spike in complex with the template, P7, P13, and P19.
| ID | Van der Waal Energy (kJ/mol) | Electrostatic Energy (kJ/mol) | Polar Solvation Energy (kJ/mol) | SASA Energy (kJ/mol) | Binding Energy (kJ/mol) |
|---|---|---|---|---|---|
| Template | −263.9 | −782.2 | 795.9 | −35.9 | −286.2 |
| P7 | −244.9 | −631.2 | 660.6 | −32.7 | −248.2 |
| P13 | −222.6 | −479.9 | 563.2 | −29.6 | −169.0 |
| P19 | −252.6 | −739.7 | 726.0 | −34.8 | −301.2 |
Fig. 7The representations of the best docking pose of top three peptides (A) P7, B) P13, and C) P19) bound to the RBD (gray) domain of the SARS-CoV-2 with the best docking scores. The surface regions indicate RBD position in receptor recognition.
The comparison of interactions between ACE2 host receptor and spike RBD domain when the final designed peptides interfere with their contact. The residues involved in H-binding are indicated in bold.
| ID | Residues | |
|---|---|---|
| Spike RBD | ACE2 | |
| P7 | Thr27, | |
| P13 | Thr27, Phe28, | |
| P19 | ||